国家药监局：开展药品经营环节“清源”巩固提升行动 持续健全药品监管法律法规体系

Core Viewpoint - The national drug supervision management conference emphasized key tasks for achieving a good start in the 14th Five-Year Plan by 2026, focusing on drug safety, industry development, legal regulation, and modernization of drug supervision [1] Group 1: Drug Safety - The conference highlighted the need to ensure high-level drug safety by improving the drug safety responsibility system and enhancing the supervision of clinical trials [1] - There will be increased inspections and sampling for key varieties, particularly those selected in centralized procurement [1] - The conference called for strengthening the regulation of online sales and maintaining a strict bottom line for drug safety [1] Group 2: Industry Development - Support for the pharmaceutical industry will be enhanced through comprehensive reforms in drug regulation, with a focus on early intervention and tailored guidance for key products [1] - The conference aims to promote innovation in drug research and development, as well as the development of traditional Chinese medicine and high-level self-reliance in medical devices [1] - There is an emphasis on fostering the growth of the beautiful economy within the pharmaceutical sector [1] Group 3: Legal Regulation - Continuous improvement of the legal and regulatory framework for drug supervision is a priority, including enhancing the authority and credibility of administrative law enforcement [1] - The conference plans to increase legal awareness among enterprises and grassroots organizations to solidify the legal foundation of drug supervision [1] Group 4: Modernization of Drug Supervision - The conference aims to develop a high-quality "14th Five-Year" drug planning and promote the integration of national drug supervision [1] - There will be a focus on building a capable regulatory workforce and enhancing technological support for drug supervision [1] - The conference also emphasizes the importance of participating in global drug safety governance to elevate China's international influence in drug regulation [1]